Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 5,600 shares of the company’s stock in a transaction on Monday, November 28th. The shares were bought at an average price of $10.61 per share, for a total transaction of $59,416.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $32,561,570.11. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, November 23rd, Phillip Md Et Al Frost acquired 4,300 shares of Opko Health stock. The stock was acquired at an average price of $10.09 per share, for a total transaction of $43,387.00.
  • On Tuesday, November 22nd, Phillip Md Et Al Frost acquired 5,400 shares of Opko Health stock. The stock was acquired at an average price of $10.28 per share, for a total transaction of $55,512.00.
  • On Monday, November 21st, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was acquired at an average price of $10.41 per share, for a total transaction of $37,476.00.
  • On Friday, November 18th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was acquired at an average price of $10.38 per share, for a total transaction of $18,684.00.
  • On Wednesday, November 16th, Phillip Md Et Al Frost acquired 4,300 shares of Opko Health stock. The stock was acquired at an average price of $10.13 per share, for a total transaction of $43,559.00.
  • On Friday, November 11th, Phillip Md Et Al Frost acquired 14,600 shares of Opko Health stock. The stock was acquired at an average price of $9.46 per share, for a total transaction of $138,116.00.
  • On Wednesday, November 9th, Phillip Md Et Al Frost acquired 5,400 shares of Opko Health stock. The stock was acquired at an average price of $9.33 per share, for a total transaction of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost acquired 23,100 shares of Opko Health stock. The stock was acquired at an average price of $9.22 per share, for a total transaction of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was acquired at an average price of $9.48 per share, for a total transaction of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was acquired at an average price of $9.49 per share, for a total transaction of $94,900.00.

Opko Health Inc. (NASDAQ:OPK) traded up 0.09% during midday trading on Tuesday, hitting $10.63. The stock had a trading volume of 317,658 shares. The stock’s market cap is $5.93 billion. The company has a 50-day moving average price of $9.76 and a 200-day moving average price of $9.88. Opko Health Inc. has a 52 week low of $7.12 and a 52 week high of $11.85.

Opko Health (NASDAQ:OPK) last issued its earnings results on Monday, November 7th. The company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. The company had revenue of $298 million for the quarter, compared to analyst estimates of $322 million. During the same period in the prior year, the firm earned $0.25 earnings per share. Opko Health’s revenue for the quarter was up 108.4% on a year-over-year basis. Equities analysts expect that Opko Health Inc. will post ($0.08) EPS for the current year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

ILLEGAL ACTIVITY WARNING: “Opko Health Inc. (OPK) CEO Acquires $59,416.00 in Stock” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/opko-health-inc-opk-ceo-acquires-59416-00-in-stock.html.

Several equities analysts recently weighed in on the stock. Jefferies Group reissued a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. TheStreet cut shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, November 9th. Oppenheimer Holdings Inc. reissued a “market perform” rating on shares of Opko Health in a research note on Thursday, August 11th. JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Finally, Zacks Investment Research cut shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 19th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $13.17.

Several institutional investors have recently modified their holdings of the company. Whalerock Point Partners LLC bought a new stake in Opko Health during the third quarter worth approximately $2,100,000. Piedmont Investment Advisors LLC bought a new stake in Opko Health during the third quarter worth approximately $622,000. Price T Rowe Associates Inc. MD raised its stake in Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock worth $10,038,000 after buying an additional 28,700 shares during the last quarter. Finally, LPL Financial LLC raised its stake in Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock worth $142,000 after buying an additional 504 shares during the last quarter. 22.27% of the stock is currently owned by institutional investors.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.